PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer

A highly anticipated topic at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, was immune checkpoint inhibitor data for bladder cancer. Here, Thomas Powles, MD, of Barts Cancer Ins... Author: VJOncology Added: 02/09/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts